C1orf131: A Potential Drug Target for Various Diseases (G128061)

Target Name: C1orf131

NCBI ID: G128061

C1orf131

C1orf131: A Potential Drug Target for Various Diseases

C1orf131, also known as Chromosome 1 open reading frame 131, and its transcript variant 1, is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. The gene is located on chromosome 1 and encodes a protein known as C1orf131, which is a key regulator of cell division and growth.

C1orf131 is a 21-kDa protein that is expressed in almost all human tissues. It plays a crucial role in the regulation of cell proliferation, differentiation, and survival. The protein is composed of 1,942 amino acids and contains several unique features that make it a potential drug target.

One of the key features of C1orf131 is its ability to interact with various transcription factors, including T-cell factor (TGF-β), which plays a critical role in cell growth, differentiation, and survival. C1orf131 has been shown to physically interact with TGF-β and regulate its activity. This interaction between C1orf131 and TGF-β suggests that it may be a useful target for drugs that are designed to inhibit TGF-β signaling.

Another potential mechanism by which C1orf131 may be targeted by drugs is its role in the regulation of the Notch signaling pathway. Notch is a transmembrane protein that plays a critical role in the regulation of stem cell proliferation and differentiation. C1orf131 has been shown to interact with Notch and regulate its activity. This interaction between C1orf131 and Notch suggests that it may be a useful target for drugs that are designed to inhibit Notch signaling.

In addition to its potential role in the regulation of TGF-β and Notch signaling pathways, C1orf131 has also been shown to play a role in the regulation of cell adhesion. The protein is involved in the regulation of tight junction formation, which is critical for the proper functioning of cells that are composed of two separate layers. This suggests that C1orf131 may be a useful target for drugs that are designed to modulate tight junction formation.

C1orf131 has also been shown to play a role in the regulation of cell survival. The protein is involved in the regulation of cell cycle progression, which is critical for the proper functioning of cells. This suggests that C1orf131 may be a useful target for drugs that are designed to inhibit cell cycle progression.

Given its involvement in the regulation of cell division and growth, C1orf131 is a potential drug target for a wide range of diseases. One of the most promising areas of research is the development of drugs that are designed to inhibit the activity of C1orf131. These drugs could be used to treat a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

In conclusion, C1orf131 is a gene that has been identified as a potential drug target and biomarker for a wide range of diseases. Its unique features, including its ability to interact with transcription factors and signaling pathways, make it an attractive target for drugs that are designed to inhibit its activity. Further research is needed to fully understand the role of C1orf131 in disease and to develop effective treatments.

Protein Name: Chromosome 1 Open Reading Frame 131

Functions: Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome. Prevents helicase DHX37 to be recruited before post-A1 state

The "C1orf131 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1orf131 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets